TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03420092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Form 1 of AZD5718 tablets
Description: The participants will be dosed with Form 1 of AZD5718 following an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Form 2 of AZD5718 tablets
Description: The participants will be dosed with Form 2 of AZD5718 following an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Form 3 of AZD5718 tablets
Description: The participants will be dosed with Form 3 of AZD5718 following an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Form 4 of AZD5718 tablets
Description: The participants will be dosed with Form 4 of AZD5718 following an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Form 5 of AZD5718 tablets
Description: The participants will be dosed with Form 5 of AZD5718 following an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selected form (Form 2 - 5) of AZD5718 tablets
Description: The participant will be administered with selected form (one of Form 2-5) of AZD5718 tablets 30 minutes after start of the meal.
Study: NCT00009945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clodronate
Description: 1600 mg PO daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 pills PO daily
Study: NCT03469401

Intervention type: OTHER
Intervention: Intervention
Description: Evaluation of sensibility, specificity, negative and positive predictive value of BD glucan in peritoneal fluid for diagnosis of fungal peritonitis, compared with fungal culture
Study: NCT00840840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL
Description: 1 x 600 mg/42.9 mg/5 mL, single-dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Augmentin ES-600™
Description: 1 x 600 mg/42.9 mg/5 mL, single-dose fasting
Study: NCT03187821

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser peripheral iridotomy
Description: location of laser peripheral iridotomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser peripheral iridotomy
Description: location of laser peripheral iridotomy
Study: NCT01859650

Intervention type: OTHER
Intervention: MR and CT imaging
Study: NCT01065129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Study: NCT02151539

Intervention type: OTHER
Intervention: medical chart review
Description: Ancillary studies
Study: NCT01993186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UX007
Description: oral liquid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral liquid
Study: NCT04320563

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Rexon-eye
Description: This treatment involved the technology known as quantum molecular resonance (QMR) which has emerged as a new treatment for all types of dry eyes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rexon-eye
Description: This treatment involved the technology known as quantum molecular resonance (QMR) which has emerged as a new treatment for all types of dry eyes.
Study: NCT03862547

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: A peripheral blood sample from the cubital vein
Description: Evaluation of NGF and Cytokine levels A portion of each blood sample and medium conditioned by PBMC will be used for the enzyme immunoassay of NGF and pro and anti-inflammatory cytokine levels (TNF alfa and IL-10).~Expression analysis of TrKA and p75NTR receptors and intracellular cytokines in PBMCs The remaining part of each blood sample and PBMC of the in vitro experiment will be used for the cytofluorimetric evaluation of the expression of TrKA, p75NTR and the pro and anti-inflammatory cytokines and reactive oxygen species.
Study: NCT02151539

Intervention type: OTHER
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT04084795

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Eye Movement Desensitization and Reprocessing therapy
Description: EMDR is a psychotherapeutic approach using a standardized 8-phase protocol to alleviate the distress associated with traumatic memories, facilitating the access to and processing of traumatic memories. Patients will receive 20 individual EMDR sessions of 60 minutes each using the standard protocol, as well as a specific pain protocol and the fibromyalgia protocol. EMDR is an integrative psychotherapy that uses standardized protocols and elements of cognitive-behavioral, interpersonal, and body-centered therapies, as well as dual stimulation (e.g., side-to-side eye movements).~The current standard protocol includes eight phases:~Patient history. Patient preparation. Patient assessment. Memory desensitization. Installing the positive cognition. Body scan. Closure. Reevaluation.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Eye Movement Desensitization and Reprocessing therapy
Description: EMDR is a psychotherapeutic approach using a standardized 8-phase protocol to alleviate the distress associated with traumatic memories, facilitating the access to and processing of traumatic memories. Patients will receive 20 individual EMDR sessions of 60 minutes each using the standard protocol, as well as a specific pain protocol and the fibromyalgia protocol. EMDR is an integrative psychotherapy that uses standardized protocols and elements of cognitive-behavioral, interpersonal, and body-centered therapies, as well as dual stimulation (e.g., side-to-side eye movements).~The current standard protocol includes eight phases:~Patient history. Patient preparation. Patient assessment. Memory desensitization. Installing the positive cognition. Body scan. Closure. Reevaluation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multifocal transcranial Current Stimulation
Description: MtCS represents a promising intervention option, given its capacity to modulate cerebral excitability in a simple, safe manner. F3 anodal; AF3, FC1, FC3, FC5, F5, return montage will be used with the anode over the left DLPFC. Half of the patients will receive active stimulation and the other half sham stimulation. Active stimulation will consist of 1mA MtDCS for 20 minutes applied immediately before EMDR sessions. The same protocol and montage will be used for sham stimulation.
Study: NCT03997890

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery with binocular implantation of either Symfony (ZXR00) or Symfony toric (ZXT) IOLs
Description: After creating an initial side port incision with a 15-degree blade, 3-step clear corneal incisions were made using a 2.5 mm disposable metal blade. Sodium hyaluronate 1.0% (Healon; Abbott Medical Optics) was then injected into the anterior chamber. A continuous curvilinear capsulorrhexis, measuring 5.5 mm in diameter, was generated using a 26 gauge bent needle. After hydrodissection, phacoemulsification was done to remove nuclear fragments and aspiration of residual cortex. In all eyes, a Symfony or Symfony toric IOL was implanted in the capsular bag using a disposable implantation system. Irrigation and aspiration were performed to minimize ophthalmic viscoelastic surgical device retention at the end of surgery. The main incision and side port were sealed with stromal hydration using a balanced salt solution.
Study: NCT04173611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXPAREL
Description: Injection into the Intrathecal space.
Study: NCT03095599

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVACFLU-S
Description: IVACFLU-S is seasonal inactivated, split virion, trivalent influenza vaccine (A/H3N2, A/H1N1, and B), produced in GCP facility by IVAC uses embryonated chicken eggs. This vaccine is purified by sucrose gradient ultracentrifugation (Alfa Wassermann, West Caldwell, NJ), and inactivated with formaldehyde. Each 0.5 mL dose of vaccine contains~* NYMC X-179A (A/California/7/2009) (H1N1) - 15μg hemagglutinin (HA)~* NYMC X-263B (A/HongKong/4801/2014) (H3N2) - 15μg HA~* NYMC BX-35 (B/Brisbane/60/2008) (B) - 15μg HA
Study: NCT04173611

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: Injection into the Intrathecal space.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Injection into the Intrathecal space.
Study: NCT00156182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asoprisnil
Description: 10mg Tablet, oral Daily for 6 months
Study: NCT04272437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concentrated herbal extract granules TRA
Description: Concentrated herbal extract granules Subjects in the TRA group orally ingested one package of granules (5 g/package) two times daily with warm water after lunch and dinner for 6 consecutive weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects in the placebo group orally ingested one package of granules (5 g/package) two times daily with warm water after lunch and dinner for 6 consecutive weeks.
Study: NCT03544242

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: A saline infusion will be administered during the pre-isolation and post-isolation phases.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre-Isolation Infusion
Description: A nitrite infusion will be administered during the pre-isolation phase and a saline infusion will be administered during the post-isolation phase.
Study: NCT04227522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: A starting dose of 600 mg Rucaparib is taken twice daily orally by the patients as maintenance after previous maintenance therapy (Bevacizumab) for a period of 12 to 15 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo is taken daily orally by the patients as maintenance after previous maintenance therapy (Bevacizumab) for a period of 12 to 15 months.
Study: NCT03544242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-Isolation Infusion
Description: A saline infusion will be administered during the pre-isolation phase and a nitrite infusion will be administered during the reperfusion phase.
Study: NCT00064324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: perifosine
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03095599

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phosphate buffered saline with pH 7.2; 0.5 ml/per dose
Study: NCT04689022

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mississippi Scale for Combat-Related PTSD (M-PTSD)
Description: The treatment outcome rate was assessed by the Mississippi Scale for Combat-Related PTSD (M-PTSD). A positive outcome rate is represented with the patient post-discharge positive coping, which corresponds to 94-58 points, observed in 39 patients (17.9%). A treatment failure is regarded as the absent PTSD treatment effect after discharge, which corresponds to 148-113 points, observed in 5 patients (2.3%) and psychic disorders, which correspond to 112-95 points, observed in 174 patients (79,8%).
Study: NCT00064324

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT00690027

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Emergency portacaval shunt

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Emergency and long-term endoscopic sclerotherapy
Study: NCT02045108

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Retraining

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Retraining

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham TDCS

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TDCS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active TDCS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active TDCS

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sham Retraining

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Retraining
Study: NCT00976443

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BTA
Description: BTA 100 or 300 U, endoscopic ultrasound (EUS) guided injections into gastric antrum
Study: NCT03148171

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: WERK Supportive Contact
Description: Provide emotional support and practical support. Support friend/family by helping him to stay engaged in PrEP Care.
Study: NCT03509753

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Fiber
Description: See intervention description.
Study: NCT00976443

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BTA
Description: BTA 100 or 300 U, endoscopic ultrasound (EUS) guided injections into gastric antrum

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (normal saline)
Description: Placebo (normal saline), gastric injections of normal saline
Study: NCT00828321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg capsule
Description: 1 x 10 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Altace® 10 mg capsule
Description: 1 x 10 mg
Study: NCT03444883

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ilaprazole
Description: 10mgx2 tablet once daily for weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ilaprazole
Description: 10mgx2 tablet once daily for weeks
Study: NCT03368209

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WM3.4
Description: Investigational Medical Device collecting spectral raman data from tissue.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WM3.4
Description: Investigational Medical Device collecting spectral raman data from tissue.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WM3.4
Description: Investigational Medical Device collecting spectral raman data from tissue.
Study: NCT00003223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fenretinide
Description: 200 mg/day PO, days 1-25 q 28 days x 6 cycles.
Study: NCT04488380

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dental restoration
Description: Restoration of carious mandibular 2nd molar teeth either with high viscosity glass ionomer or nanohybrid composite resin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dental restoration
Description: Restoration of carious mandibular 2nd molar teeth either with high viscosity glass ionomer or nanohybrid composite resin
Study: NCT00323258

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: oral education & written tips for remembering medications
Description: Clinical pharmacist will review purpose of medications of interest (beta-blockers, statins, Angiotensin Converting Enzyme Inhibitor (ACEI)/Angiotensin Receptor Blocker (ARB), aspirin, and other anti-platelets) with the subject. A written list of tips for remembering medications will be provided and reviewed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pill box
Description: Subject is provided a pill box and briefly instructed on how to use the box.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pocket medication card
Description: Subject is provided with a card that contains space for prescription and non-prescription medications. If desired the clinical pharmacist-investigator will complete the card for the subject.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sharing information with community pharmacist
Description: A fax is sent to the designated community pharmacy at the time of the subject's discharge from the hospital. The fax contains the subject's medications of interest, barriers to medication adherence, and physicians' contact information.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication use evaluations by community pharmacist
Description: The community pharmacist will assess use of medications of interest at time of first medication fill and by reviewing the subject's computerized medication profile at the pharmacy. Assessments occur at first visit to pharmacy, 6-weeks, 12-weeks, 18-weeks, and 24-weeks. If there are issues with any medications of interest the subject will be called. If needed, the subject's health care team will be notified.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: informing physician if patient has stopped a medication
Description: The community pharmacist or clinical pharmacist-investigator will fax the subject's physician to notify that a medication has been stopped.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine discharge counseling
Description: Both groups received routine discharge counseling performed by the patient-care nurse.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine discharge counseling
Description: Both groups received routine discharge counseling performed by the patient-care nurse.
Study: NCT03568058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: personalized vaccine
Description: Vaccine will be constructed for each subject that express multiple candidate tumor-derived neoantigens.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: personalized vaccine
Description: Vaccine will be constructed for each subject that express multiple candidate tumor-derived neoantigens.
Study: NCT03509753

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low Fiber
Description: See intervention description.
Study: NCT02828319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z-213
Description: The total iron dosage is calculated based on hemoglobin value and the patients' weight, IV on day 1, 8 and 15 (if needed)
Study: NCT04408157

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management booklet (SWitCh: Stay well during COVID-19)
Description: The purpose of this booklet is to support adjustment to the current circumstances of the COVID-19 pandemic and facilitate the development and maintenance of healthy behaviours at home. The booklet covers a range of topics, including understanding bodily sensations and symptoms of COVID-19, managing the uncertainty surrounding COVID-19, physical activity, sedentary behaviour, sleep, social support and isolation, nutrition and alcohol consumption, sex and intimate relationships, and coping with children at home. The booklet will provide structured guidance on the various topics through the use of effective behaviour change techniques, in particular self-monitoring, goal setting, and problem solving and signposting to additional helpful resources, such as drinking or nutrition tracking apps.
Study: NCT03667677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tandospirone + Amlodipine
Description: The first group will receive a 30 mg dose of tandospirone one day( a 10 mg dose of tandospirone each time and three times a day) and a 5 mg dose of amlodipine one day(a 5 mg dose of amlodipine and one time a day).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tandospirone placebo + Amlodipine
Description: The second group will receive a 30 mg dose of tandospirone placebo one day( a 10 mg dose of tandospirone placebo each time and three times a day) and a 5 mg dose of amlodipine one day(a 5 mg dose of amlodipine and one time a day).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tandospirone + Amlodipine placebo
Description: The third group will receive a 30 mg dose of tandospirone one day( a 10 mg dose of tandospirone and three times a day) and a 5 mg dose of amlodipine placebo one day(a 5 mg dose of amlodipine placebo and one time a day).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tandospirone placebo + Amlodipine placebo
Description: The fourth group will receive a 30 mg dose of tandospirone placebo one day( a 10 mg dose of tandospirone placebo each time and three times a day) and a 5 mg dose of amlodipine placebo one day(a 5 mg dose of amlodipine placebo and one time a day).
Study: NCT00778999

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marvelon
Description: oral contraceptive 1 tablet daily for 14 to 21 days
Study: NCT03587909

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phacoemulsification Cataract SUrgery
Description: Phacoemulsification in eyes with shallow anterior chamber (\<2.5mm depth)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femtosecond Cataract Surgery
Description: Femtosecond Cataract Surgery in eyes with shallow anterior chamber \< 2.5mm
Study: NCT02857023

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cogmed RM
Description: Cogmed consists of 12 increasingly challenging exercises (completed over 25 sessions spanning 5-8 weeks) that target skills involving visuo-spatial and verbal working memory.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cogmed RM
Description: Cogmed consists of 12 increasingly challenging exercises (completed over 25 sessions spanning 5-8 weeks) that target skills involving visuo-spatial and verbal working memory.
Study: NCT02168946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vabomere
Description: Vabomere for IV injection, administered as a 2 g/2 g dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best Available Therapy
Description: Antibiotic(s) chosen by Investigator
Study: NCT04374994

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avanafil 50 MG
Description: Oral phosphodiesterase type 5 inhibitors

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: lactose and maize starch, Egypt
Study: NCT02199522

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: titration induction to propofol
Description: propofol intravenously by Fresenius pump at the speed of 1 mg•kg-1•min-1, and OAA/S scale of the patients was titrated to 1
Study: NCT02235285

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: primary breast augmentation
Description: With the patient under sedative anesthesia, wide preparation and draping by using povidone-iodine are performed with using talc-free gloves and povidone-iodine gauze nipple shields. Tumescent solution is infiltrated in the precise plane. Pockets are developed precisely with blunt dissection with fingers and instruments under both direct and indirect visions simultaneously, if needed, with using endoscopy, while careful hemostasis done. After dissection, two pockets are irrigated with 300ml of single antibiotic solution without active evacuation of the irrigation. When re-draping and re-preparation by using povidone-iodine are performed before implant insertion, a new pair of talc-free gloves is used and cleansed with the single antibiotic solution.